Evaxion Biotech As Stock Performance
| EVAX Stock | USD 2.47 0.92 27.14% |
The firm shows a Beta (market volatility) of -0.13, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Evaxion Biotech are expected to decrease at a much lower rate. During the bear market, Evaxion Biotech is likely to outperform the market. At this point, Evaxion Biotech AS has a negative expected return of -1.89%. Please make sure to confirm Evaxion Biotech's information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if Evaxion Biotech AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Evaxion Biotech AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (27.14) | Five Day Return (64.56) | Year To Date Return (46.54) | Ten Year Return (99.50) | All Time Return (99.50) |
Last Split Factor 1:10 | Last Split Date 2024-01-22 |
1 | Evaxion announces business update and third quarter 2024 financial results | 10/31/2024 |
2 | ARMISTICE CAPITAL, LLC Acquires Shares in Evaxion Biotech AS - GuruFocus.com | 11/14/2024 |
3 | Evaxion Biotech stock hits 52-week low at 1.31 - Investing.com | 11/21/2024 |
4 | Evaxion Biotech Unveils Precision Cancer Vaccine Breakthrough - TipRanks | 12/03/2024 |
5 | Evaxion establishes new AI-derived precision cancer vaccine concept | 12/12/2024 |
6 | Evaxion pursues agreement with EIB to boost equity via converting debt into equity - MSN | 12/18/2024 |
7 | Evaxion announces plan to implement ADS ratio change - Seeking Alpha | 12/30/2024 |
8 | Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change | 01/10/2025 |
9 | EVAX Adjusts Share Ratio | 01/15/2025 |
10 | Mercks VC Arm Backs Evaxion Biotech in 10.8M Strategic Investment Round - StockTitan | 01/30/2025 |
| Begin Period Cash Flow | 13.2 M |
Evaxion |
Evaxion Biotech Relative Risk vs. Return Landscape
If you would invest 1,320 in Evaxion Biotech AS on November 2, 2024 and sell it today you would lose (1,073) from holding Evaxion Biotech AS or give up 81.29% of portfolio value over 90 days. Evaxion Biotech AS is currently does not generate positive expected returns and assumes 14.6481% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Evaxion, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evaxion Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evaxion Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evaxion Biotech AS, and traders can use it to determine the average amount a Evaxion Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1288
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EVAX |
Estimated Market Risk
| 14.65 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.89 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Evaxion Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evaxion Biotech by adding Evaxion Biotech to a well-diversified portfolio.
Evaxion Biotech Fundamentals Growth
Evaxion Stock prices reflect investors' perceptions of the future prospects and financial health of Evaxion Biotech, and Evaxion Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evaxion Stock performance.
| Return On Equity | -8.03 | ||||
| Return On Asset | -0.69 | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | 8.1 M | ||||
| Shares Outstanding | 5.58 M | ||||
| Price To Book | 75.74 X | ||||
| Price To Sales | 1.70 X | ||||
| Revenue | 73 K | ||||
| EBITDA | (21.4 M) | ||||
| Net Income | (22.12 M) | ||||
| Cash And Equivalents | 25.25 M | ||||
| Cash Per Share | 1.06 X | ||||
| Total Debt | 10.87 M | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 6.47 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (17.69 M) | ||||
| Earnings Per Share | (2.80) X | ||||
| Market Capitalization | 13.28 M | ||||
| Total Asset | 12.89 M | ||||
| Retained Earnings | (107.97 M) | ||||
| Working Capital | 1.27 M | ||||
About Evaxion Biotech Performance
Evaluating Evaxion Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Evaxion Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Evaxion Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.4 K | -1.5 K | |
| Return On Tangible Assets | (1.97) | (1.88) | |
| Return On Capital Employed | (4.40) | (4.18) | |
| Return On Assets | (1.97) | (1.88) | |
| Return On Equity | 4.21 | 4.42 |
Things to note about Evaxion Biotech AS performance evaluation
Checking the ongoing alerts about Evaxion Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evaxion Biotech AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evaxion Biotech AS generated a negative expected return over the last 90 days | |
| Evaxion Biotech AS has high historical volatility and very poor performance | |
| Evaxion Biotech AS has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 73 K. Net Loss for the year was (22.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Evaxion Biotech AS currently holds about 25.25 M in cash with (17.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06. | |
| Evaxion Biotech AS has a poor financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Mercks VC Arm Backs Evaxion Biotech in 10.8M Strategic Investment Round - StockTitan |
- Analyzing Evaxion Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evaxion Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Evaxion Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evaxion Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evaxion Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evaxion Biotech's stock. These opinions can provide insight into Evaxion Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.